jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

SARS-COV-2 Spike protein IgG Antibodies

Bacterial/ Viral
image

Report in 4Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Measures the level of IgG antibodies directed against the spike (S) protein of the SARS-CoV-2 virus

₹399₹1,150

65% OFF

SARS-CoV-2 Spike Protein IgG Antibodies - Comprehensive Test Guide

  • Why is it done?
    • Test Purpose: Detects IgG antibodies against the SARS-CoV-2 spike protein, indicating past or current infection or vaccine-induced immunity
    • Assess Immune Response: Evaluates the body's adaptive immune response to SARS-CoV-2 exposure or vaccination
    • Confirm Prior Infection: Identifies individuals with past COVID-19 infection, even in asymptomatic or mild cases
    • Vaccine Response Monitoring: Determines if vaccination has generated adequate antibody response and protective immunity
    • Immunocompromised Patients: Assesses antibody production in patients with weakened immune systems or on immunosuppressive therapy
    • Typical Timing: Performed 2-4 weeks after infection symptoms resolve or 2-4 weeks post-vaccination; may be repeated to monitor antibody persistence
  • Normal Range
    • Negative Result: < 0.8 S/CO (Signal-to-Cutoff ratio) or < 1.0 AU/mL (Arbitrary Units/milliliter) Indicates: No detectable antibodies; no prior infection or inadequate immune response to vaccination
    • Borderline/Inconclusive: 0.8-1.0 S/CO or 1.0-1.5 AU/mL Indicates: Uncertain immunity status; repeat testing recommended in 1-2 weeks
    • Positive Result: > 1.0 S/CO or > 1.5 AU/mL Indicates: Detectable antibodies present; evidence of prior infection or vaccine response
    • Units of Measurement: S/CO (Signal-to-Cutoff), AU/mL (Arbitrary Units per milliliter), or BAU/mL (Binding Antibody Units) depending on laboratory methodology
    • High Values (>10 S/CO): Strong antibody response; likely recent infection or recent vaccination
    • Low Positive Values (1.0-3.0 S/CO): Mild antibody response; remote infection or waning immunity over time
  • Interpretation
    • Positive IgG Antibodies: Indicates prior SARS-CoV-2 exposure (infection) or successful vaccination response. IgG appears 1-3 weeks after infection and persists long-term. Does not indicate current infection (IgM would be present for acute infection)
    • Negative IgG Antibodies: No detectable antibodies to spike protein. May indicate: no prior infection/vaccination, very recent infection (before antibodies develop), or immunocompromised state with poor antibody production
    • Serial Testing Patterns: Rising titers suggest recent infection; stable or declining titers indicate remote infection or waning vaccine immunity
    • Factors Affecting Results: Immunosuppression (reduced response), age (elderly may have lower titers), timing of test relative to infection/vaccination, variant strain exposure, medication use (corticosteroids, biologics)
    • Distinguishing Infection vs. Vaccination: This test cannot differentiate between antibodies from natural infection vs. vaccination. Combined serology (spike vs. nucleocapsid antibodies) may be used; nucleocapsid antibodies indicate natural infection only
    • Clinical Significance: Positive results suggest some level of immunity; however, antibody levels do not perfectly correlate with protection. Neutralizing antibody testing provides more specific immunity assessment
    • False Negatives: Can occur in severe immunosuppression, early infection (<2 weeks), or due to analytical sensitivity of assay
    • False Positives: Rare; may occur with cross-reactive antibodies from other coronavirus infections or technical assay issues
  • Associated Organs
    • Primary Organ System - Immune System: The adaptive immune response produces IgG antibodies in response to SARS-CoV-2 spike protein antigen
    • Secondary Organ Systems - Respiratory Tract: Site of SARS-CoV-2 replication and initial infection
    • Cardiovascular System: Endothelial cells express ACE2 receptors; SARS-CoV-2 can cause cardiac complications
    • Gastrointestinal System: ACE2 receptors present; can contribute to GI symptoms during infection
    • Neurological System: SARS-CoV-2 can affect central nervous system; antibodies may reflect neurological involvement
    • Associated Conditions with Abnormal Results: COVID-19 infection (acute/resolved), vaccine-induced immunity, long COVID syndrome
    • Complications Associated with Positive Results: Post-acute sequelae (long COVID), myocarditis, pulmonary fibrosis, thrombotic complications, multisystem inflammatory response
    • Risk in Immunocompromised Patients: Negative results despite infection or vaccination may indicate persistent viral replication or failed immune priming, requiring alternative management strategies
  • Follow-up Tests
    • SARS-CoV-2 IgM Antibodies: If acute infection is suspected; indicates recent or active infection (IgM present for 5-10 days post-infection)
    • SARS-CoV-2 Nucleocapsid Antibodies: Differentiates natural infection from vaccination; present in infection only, not vaccination
    • SARS-CoV-2 Neutralizing Antibody Testing: Assesses functional immunity and ability to neutralize virus; more specific for protective immunity than binding antibodies
    • SARS-CoV-2 PCR/Antigen Test: If active infection is suspected despite negative/borderline antibody results; detects current viral presence
    • Complete Blood Count (CBC): If immunocompromised status is suspected; assess immune cell populations
    • T-cell Response Testing (CD4/CD8 Count, Flow Cytometry): In immunocompromised patients with poor antibody response; evaluates cellular immunity
    • Immunoglobulin Panel: If primary immunodeficiency is suspected; measures total immunoglobulin production capacity
    • Repeat Spike IgG Testing: Recommended at 2-4 week intervals if borderline results obtained; helps confirm seroconversion
    • Serial Monitoring Post-Vaccination: May be repeated 6-12 months post-vaccination or after booster doses to track antibody persistence and assess need for revaccination
    • Imaging Studies (if clinically indicated): Chest X-ray, CT scan for persistent respiratory symptoms; Echocardiography for cardiac complications
  • Fasting Required?
    • Fasting Required: NO
    • Special Preparation: None required. No fasting needed; food and fluid intake do not affect antibody detection
    • Specimen Collection: Serum or plasma sample obtained via venipuncture; standard blood draw procedure
    • Medications - No Restrictions: Continue all routine medications as prescribed. Note: Immunosuppressive medications (biologics, corticosteroids, antirejection drugs) may affect antibody response but should not be withheld
    • Timing Considerations: Test should be performed at least 14 days post-infection or post-vaccination to allow adequate IgG antibody development For vaccine response assessment: 2-4 weeks post-final vaccine dose (or after booster)
    • Appointment Instructions: Can schedule test any time of day without dietary restrictions. Inform healthcare provider of any immunosuppressive conditions or medications for proper result interpretation
    • Post-Test Activity: No restrictions; normal activities can resume immediately after blood draw

How our test process works!

customers
customers